Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy.
Yeregui E, Masip J, Viladés C, Domingo P, Pacheco YM, Blanco J, Mallolas J, Alba V, Vargas M, García-Pardo G, Negredo E, Olona M, Vidal-González J, Peraire M, Martí A, Reverté L, Gómez-Bertomeu F, Leal M, Vidal F, Peraire J, Rull A. Yeregui E, et al. Among authors: vilades c. Int J Mol Sci. 2022 Feb 17;23(4):2202. doi: 10.3390/ijms23042202. Int J Mol Sci. 2022. PMID: 35216318 Free PMC article.
Lack of association of SDF-1 3'A variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 years.
Vidal F, Peraire J, Domingo P, Broch M, Knobel H, Pedrol E, Dalmau D, Viladés C, Sambeat MA, Gutiérrez C, Richart C; Chemokines and Long-Term Nonprogressor Study Group. Vidal F, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):276-9. doi: 10.1097/01.qai.0000176653.89769.4d. J Acquir Immune Defic Syndr. 2005. PMID: 16249700
Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele.
Vidal F, Viladés C, Domingo P, Broch M, Pedrol E, Dalmau D, Knobel H, Peraire J, Gutiérrez C, Sambeat MA, Fontanet A, Deig E, Cairó M, Montero M, Richart C, Mallal S; Chemokines LTNP Study Group. Vidal F, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):527-31. doi: 10.1097/01.qai.0000186362.50457.e0. J Acquir Immune Defic Syndr. 2005. PMID: 16284527
Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years.
Vidal F, Peraire J, Domingo P, Broch M, Cairó M, Pedrol E, Montero M, Viladés C, Gutiérrez C, Sambeat MA, Fontanet A, Dalmau D, Deig E, Knobel H, Sirvent JJ, Richart C, Veloso S, Saumoy M, López-Dupla M, Olona M, Cadafalch J, Fuster M, Ochoa A, Soler A, Guelar A, González J; Chemokines and Long-Term Nonprogressive HIV01 Infection Study Group. Vidal F, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):17-22. doi: 10.1097/01.qai.0000188335.86466.ea. J Acquir Immune Defic Syndr. 2006. PMID: 16340468
Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects.
Viladés C, Broch M, Plana M, Domingo P, Alonso-Villaverde C, Pedrol E, Knobel H, Dalmau D, Peraire J, Gutiérrez C, López A, Sambeat MA, Olona M, Garcia F, Richart C, Gatell JM, Vidal F; Chemokines and Long-Term Nonprogressors Study Group. Viladés C, et al. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):132-8. doi: 10.1097/QAI.0b013e31802b3147. J Acquir Immune Defic Syndr. 2007. PMID: 17091019
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M, Ribera E, Suárez-Lozano I, Domingo P, Pedrol E, López-Aldeguer J, Muñoz A, Viladés C, Sánchez T, Viciana P, Teira R, García-Alcalde ML, Vergara A, Lozano F, Galindo MJ, Cosin J, Roca B, Terrón A, Geijo P, Vidal F, Garrido M; VACH Cohort Study Group. Crespo M, et al. Among authors: vilades c. J Antimicrob Chemother. 2009 Jan;63(1):189-96. doi: 10.1093/jac/dkn450. Epub 2008 Nov 6. J Antimicrob Chemother. 2009. PMID: 18988678 Clinical Trial.
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group. Mallolas J, et al. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f. J Acquir Immune Defic Syndr. 2009. PMID: 19390327 Clinical Trial.
109 results